Literature DB >> 32865810

Clinical plasma concentration of vinpocetine does not affect osteogenic differentiation of mesenchymal stem cells.

Esma Yıldırım1, Gulay Sezer2,3.   

Abstract

AIM: Vinpocetine (Vin) has long been used as a medicine to treat cerebrovascular disorders and as a dietary supplement to improve cognitive functions. Previous studies have revealed that the transcription factor nuclear factor kappa B (NF-κB) activity plays an important role in osteogenic differentiation of mesenchymal stem cells (MSC). Vin inhibits NF-κB-dependent inflammatory responses; however, the effect of Vin on the osteogenic differentiation of MSCs has not been reported. In this study, we aimed to the investigate effect of Vin on the osteogenic differentiation of rat bone marrow-derived MSCs (BMSCs).
METHODS: We treated BMSCs with clinical plasma (0.17 µM) or higher concentrations (5 and 20 µM) of Vin with no significant effect on the cell viability. Alizarin Red S and alkaline phosphatase (ALP) stainings were used to evaluate mineralizations on days 14 and 21. Moreover, expressions of target genes were detected using qRT-PCR analysis.
RESULTS: Osteogenic differentiation of BMSCs did not significantly change with Vin's clinical plasma concentration, but significantly decreased with higher concentrations. Calcium mineralization, ALP staining and mRNA gene expressions of Runx2 and ALP were decreased significantly with high concentrations of Vin, paticularly on day 21.
CONCLUSION: Our in vitro findings suggest that clinically relevant concentration of Vin seems safe to use in elderly patients with respect to osteoporosis. On the other hand, Vin at high concentrations appears to be harmful to bone homeostasis.

Entities:  

Keywords:  ALP; Mesenchymal stem cells; NF-kappa B; Osteogenic differentation; Runx2; Vinpocetine

Year:  2020        PMID: 32865810     DOI: 10.1007/s43440-020-00153-8

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  33 in total

1.  Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.

Authors:  Kye-Im Jeon; Xiangbin Xu; Toru Aizawa; Jae Hyang Lim; Hirofumi Jono; Dong-Seok Kwon; Jun-Ichi Abe; Bradford C Berk; Jian-Dong Li; Chen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-06       Impact factor: 11.205

2.  Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss.

Authors:  Meipeng Zhu; Hui Liu; Kai Sun; Jian Liu; Yan Mou; Dahu Qi; Chuankun Zhou; Maihaiti Abudunaibi; Bahebieergan Tasiken; Jianwen Li; Hao Cheng; Hui Huang
Journal:  Biomed Pharmacother       Date:  2019-12-14       Impact factor: 6.529

3.  The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1β and TNF-α expression in rat hippocampus.

Authors:  Carlos D Gómez; Rudolf M Buijs; María Sitges
Journal:  J Neurochem       Date:  2014-06-27       Impact factor: 5.372

Review 4.  Role of vinpocetine in cerebrovascular diseases.

Authors:  Sazal Patyar; Ajay Prakash; Manish Modi; Bikash Medhi
Journal:  Pharmacol Rep       Date:  2011       Impact factor: 3.024

Review 5.  Role of sodium channel inhibition in neuroprotection: effect of vinpocetine.

Authors:  P Bönöczk; B Gulyás; V Adam-Vizi; A Nemes; E Kárpáti; B Kiss; M Kapás; C Szántay; I Koncz; T Zelles; A Vas
Journal:  Brain Res Bull       Date:  2000-10       Impact factor: 4.077

6.  Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions.

Authors:  Alexandre E Medina
Journal:  Front Neurosci       Date:  2011-02-18       Impact factor: 4.677

Review 7.  Osteoporosis after stroke: a review of the causes and potential treatments.

Authors:  Stefano Carda; Carlo Cisari; Marco Invernizzi; Maurizio Bevilacqua
Journal:  Cerebrovasc Dis       Date:  2009-06-30       Impact factor: 2.762

8.  Relationship between senile osteoporosis and cardiovascular and cerebrovascular diseases.

Authors:  Xiaoying Hu; Shucan Ma; Caixia Yang; Weiwei Wang; Liman Chen
Journal:  Exp Ther Med       Date:  2019-04-23       Impact factor: 2.447

Review 9.  Role of vinpocetine in ischemic stroke and poststroke outcomes: A critical review.

Authors:  Hayder M Al-Kuraishy; Ali I Al-Gareeb; Marwa Thaier Naji; Farah Al-Mamorry
Journal:  Brain Circ       Date:  2020-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.